Reverse ventricular remodelling after cardiac resynchronization therapy is associated with a reduction in serum tenascin-C and plasma matrix metalloproteinase-9 levels

European Journal of Heart Failure

Volumn 9, Issue 10, 2007, Pages 1058-1063

  Hessel, Marleen H M ^a   Bleeker, Gabe B ^a   Bax, Jeroen J ^a   Henneman, Maureen M ^a   den Adel, Brigit ^a   Klok, Margreet ^a   Schalij, M J ^a   Atsma, Douwe E ^a   van der Laarse, Arnoud ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Brain natriuretic peptide; Cardiac resynchronization therapy; Extracellular matrix; Left ventricular remodelling; Matrix metalloproteinases; Tenascin C

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BIOLOGICAL MARKER; GELATINASE A; GELATINASE B; TENASCIN;

ADULT; AGED; ARTICLE; CARDIAC RESYNCHRONIZATION THERAPY; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; EXTRACELLULAR MATRIX; FEMALE; FOLLOW UP; HEART FAILURE; HEART LEFT VENTRICLE CONTRACTION; HEART LEFT VENTRICLE VOLUME; HEART VENTRICLE REMODELING; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TREATMENT RESPONSE;

AGED; BIOLOGICAL MARKERS; CARDIAC PACING, ARTIFICIAL; EXTRACELLULAR MATRIX; FEMALE; HEART VENTRICLES; HUMANS; HYPERTROPHY, LEFT VENTRICULAR; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PROSPECTIVE STUDIES; TENASCIN; TREATMENT OUTCOME; VENTRICULAR DYSFUNCTION, LEFT; VENTRICULAR REMODELING;

EID: 34548815254     PISSN: 13889842     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejheart.2007.07.007     Document Type: Article

References (33)

1. Strickberger S.A., Conti J., Daoud E.G., et al. Patient selection for cardiac resynchronization therapy: from the Council on Clinical Cardiology Subcommittee on Electrocardiography and Arrhythmias and the Quality of Care and Outcomes Research Interdisciplinary Working Group, in collaboration with the Heart Rhythm Society. Circulation 111 (2005) 2146-2150
2. Abraham W.T., Fisher W.G., Smith A.L., et al. Cardiac resynchronization in chronic heart failure. N Engl J Med 346 (2002) 1845-1853
3. John Sutton M.G., Plappert T., Abraham W.T., et al. Effect of cardiac resynchronization therapy on left ventricular size and function in chronic heart failure. Circulation 107 (2003) 1985-1990
4. Cleland J.G., Daubert J.C., Erdmann E., et al. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med 352 (2005) 1539-1549
5. Molhoek S.G., Bax J.J., van Erven L., et al. Atrial and brain natriuretic peptides as markers of response to resynchronisation therapy. Heart 90 (2004) 97-98
6. Yu C.M., Bleeker G.B., Fung J.W., et al. Left ventricular reverse remodeling but not clinical improvement predicts long-term survival after cardiac resynchronization therapy. Circulation 112 (2005) 1580-1586
7. Samuel J.L., Corda S., Chassagne C., and Rappaport L. The extracellular matrix and the cytoskeleton in heart hypertrophy and failure. Heart Fail Rev 5 (2000) 239-250
8. Jugdutt B.I. Matrix metalloproteinases as markers of adverse remodeling after myocardial infarction. J Card Fail 12 (2006) 73-76
9. Wagner D.R., Delagardelle C., Ernens I., Rouy D., Vaillant M., and Beissel J. Matrix metalloproteinase-9 is a marker of heart failure after acute myocardial infarction. J Card Fail 12 (2006) 66-72
10. Sato A., Aonuma K., Imanaka-Yoshida K., et al. Serum tenascin-C might be a novel predictor of left ventricular remodeling and prognosis after acute myocardial infarction. J Am Coll Cardiol 47 (2006) 2319-2325
11. Nilsson J.C., Groenning B.A., Nielsen G., et al. Left ventricular remodeling in the first year after acute myocardial infarction and the predictive value of N-terminal pro brain natriuretic peptide. Am Heart J 143 (2002) 696-702
12. Bax J.J., Bleeker G.B., Marwick T.H., et al. Left ventricular dyssynchrony predicts response and prognosis after cardiac resynchronization therapy. J Am Coll Cardiol 44 (2004) 1834-1840
13. Schiller N.B., Shah P.M., Crawford M., et al. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, subcommittee on quantitation of two-dimensional echocardiograms. J Am Soc Echocardiogr 2 (1989) 358-367
14. Kleiner D.E., and Stetler-Stevenson W.G. Quantitative zymography: detection of picogram quantities of gelatinases. Anal Biochem 218 (1994) 325-329
15. Spinale F.G. Matrix metalloproteinases: regulation and dysregulation in the failing heart. Circ Res 90 (2002) 520-530
16. Imanaka-Yoshida K., Hiroe M., and Yoshida T. Interaction between cell and extracellular matrix in heart disease: multiple roles of tenascin-C in tissue remodeling. Histol Histopathol 19 (2004) 517-525
17. Imanaka-Yoshida K., Matsumoto K., Hara M., Sakakura T., and Yoshida T. The dynamic expression of tenascin-C and tenascin-X during early heart development in the mouse. Differentiation 71 (2003) 291-298
18. Imanaka-Yoshida K., Hiroe M., Nishikawa T., et al. Tenascin-C modulates adhesion of cardiomyocytes to extracellular matrix during tissue remodeling after myocardial infarction. Lab Invest 81 (2001) 1015-1024
19. Morimoto S., Imanaka-Yoshida K., Hiramitsu S., et al. Diagnostic utility of tenascin-C for evaluation of the activity of human acute myocarditis. J Pathol 205 (2005) 460-467
20. Tamura A., Kusachi S., Nogami K., et al. Tenascin expression in endomyocardial biopsy specimens in patients with dilated cardiomyopathy: distribution along margin of fibrotic lesions. Heart 75 (1996) 291-294
21. Jian B., Jones P.L., Li Q., Mohler III E.R., Schoen F.J., and Levy R.J. Matrix metalloproteinase-2 is associated with tenascin-C in calcific aortic stenosis. Am J Pathol 159 (2001) 321-327
22. Nagase H. Activation mechanisms of matrix metalloproteinases. Biol Chem 378 (1997) 151-160
23. Baker A.H., Edwards D.R., and Murphy G. Metalloproteinase inhibitors: biological actions and therapeutic opportunities. J Cell Sci 115 (2002) 3719-3727
24. Yan A.T., Yan R.T., Spinale F.G., et al. Plasma matrix metalloproteinase-9 level is correlated with left ventricular volumes and ejection fraction in patients with heart failure. J Card Fail 12 (2006) 514-519
25. Yamazaki T., Lee J.D., Shimizu H., Uzui H., and Ueda T. Circulating matrix metalloproteinase-2 is elevated in patients with congestive heart failure. Eur J Heart Fail 6 (2004) 41-45
26. Peterson J.T., Hallak H., Johnson L., et al. Matrix metalloproteinase inhibition attenuates left ventricular remodeling and dysfunction in a rat model of progressive heart failure. Circulation 103 (2001) 2303-2309
27. Li Y.Y., Feng Y., McTiernan C.F., et al. Downregulation of matrix metalloproteinases and reduction in collagen damage in the failing human heart after support with left ventricular assist devices. Circulation 104 (2001) 1147-1152
28. Nishikawa N., Yamamoto K., Sakata Y., et al. Differential activation of matrix metalloproteinases in heart failure with and without ventricular dilatation. Cardiovasc Res 57 (2003) 766-774
29. Kalembeyi I., Inada H., Nishiura R., Imanaka-Yoshida K., Sakakura T., and Yoshida T. Tenascin-C upregulates matrix metalloproteinase-9 in breast cancer cells: direct and synergistic effects with transforming growth factor beta1. Int J Cancer 105 (2003) 53-60
30. de Lemos J.A., McGuire D.K., and Drazner M.H. B-type natriuretic peptide in cardiovascular disease. Lancet 362 (2003) 316-322
31. Nagaya N., Nishikimi T., Goto Y., et al. Plasma brain natriuretic peptide is a biochemical marker for the prediction of progressive ventricular remodeling after acute myocardial infarction. Am Heart J 135 (1998) 21-28
32. Kawakami R., Saito Y., Kishimoto I., et al. Overexpression of brain natriuretic peptide facilitates neutrophil infiltration and cardiac matrix metalloproteinase-9 expression after acute myocardial infarction. Circulation 110 (2004) 3306-3312
33. Bruggink A.H., de Jonge N., van Oosterhout M.F., et al. Brain natriuretic peptide is produced both by cardiomyocytes and cells infiltrating the heart in patients with severe heart failure supported by a left ventricular assist device. J Heart Lung Transplant 25 (2006) 174-180